Q3 2024 Holdings
Filed 2024-11-14 | 11 holdings | $160.0M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Bicara Therapeutics Inc.(BCAX) | Common Stock | 055477103 | $56.2M | 2,204,650 | 35.1% |
| Nuvation Bio(NUVB) | Common Stock Class A | 67080N101 | $29.9M | 13,072,340 | 18.7% |
| Replimune Group(REPL) | Common Stock | 76029N106 | $27.0M | 2,461,319 | 16.9% |
| Lexeo Therapeutics(LXEO) | Common Stock | 52886X107 | $21.3M | 2,355,904 | 13.3% |
| enGene Holdings Inc.(ENGN) | Common Stock | 29286M105 | $7.1M | 1,076,357 | 4.4% |
| Alumis Inc(ALMS) | Common Stock | 022307102 | $7.0M | 653,223 | 4.4% |
| Ikena Oncology | Common Stock | 45175G108 | $3.9M | 2,249,123 | 2.4% |
| Sana Biotechnology, Inc.(SANA) | Common Stock | 799566104 | $3.5M | 843,750 | 2.2% |
| Immunic Inc(IMUX) | Common Stock | 4525EP101 | $3.0M | 1,788,160 | 1.8% |
| enGene Holdings Inc.(ENGNW) | Warrant | 29286M113 | $675.2K | 321,502 | 0.4% |
| Syros Pharmaceuticals(SYRS) | Common Stock | 87184Q206 | $540.2K | 251,270 | 0.3% |